Fady Ibraham Malik's most recent trade in Cytokinetics Inc was a trade of 3,500 Non-Qualified Stock Option (Right to Buy) done . Disclosure was reported to the exchange on July 21, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jul 2026 | 3,500 | 33,886 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.80 per share. | 21 Jul 2026 | 3,500 | 157,402 (0%) | 0% | 7.8 | 27,300 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 80.59 per share. | 21 Jul 2026 | 3,500 | 153,902 (0%) | 0% | 80.6 | 282,065 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2026 | 3,500 | 37,386 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 86.62 per share. | 07 Jul 2026 | 3,500 | 153,902 (0%) | 0% | 86.6 | 303,170 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.80 per share. | 07 Jul 2026 | 3,500 | 157,402 (0%) | 0% | 7.8 | 27,300 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jun 2026 | 3,500 | 40,886 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 79.51 per share. | 23 Jun 2026 | 3,500 | 153,902 (0%) | 0% | 79.5 | 278,285 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.80 per share. | 23 Jun 2026 | 3,500 | 157,402 (0%) | 0% | 7.8 | 27,300 | Common Stock |
| Rocket Pharmaceuticals Inc | Fady Ibraham Malik | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2026 | 64,860 | 64,860 | - | - | Stock Option (Right to Buy) | |
| Rocket Pharmaceuticals Inc | Fady Ibraham Malik | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2026 | 22,862 | 52,862 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.80 per share. | 09 Jun 2026 | 3,500 | 157,402 (0%) | 0% | 7.8 | 27,300 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2026 | 3,500 | 44,386 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 67.98 per share. | 09 Jun 2026 | 3,500 | 153,902 (0%) | 0% | 68.0 | 237,930 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 May 2026 | 3,500 | 47,886 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.80 per share. | 19 May 2026 | 3,500 | 157,402 (0%) | 0% | 7.8 | 27,300 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 75.69 per share. | 19 May 2026 | 3,500 | 153,902 (0%) | 0% | 75.7 | 264,915 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.80 per share. | 05 May 2026 | 3,500 | 157,402 (0%) | 0% | 7.8 | 27,300 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 77.37 per share. | 05 May 2026 | 3,500 | 153,902 (0%) | 0% | 77.4 | 270,795 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2026 | 3,500 | 51,386 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 65.69 per share. | 21 Apr 2026 | 3,500 | 153,902 (0%) | 0% | 65.7 | 229,915 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Apr 2026 | 3,500 | 54,886 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.80 per share. | 21 Apr 2026 | 3,500 | 157,402 (0%) | 0% | 7.8 | 27,300 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.80 per share. | 07 Apr 2026 | 3,500 | 157,402 (0%) | 0% | 7.8 | 27,300 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2026 | 3,500 | 58,386 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 65.21 per share. | 07 Apr 2026 | 3,500 | 153,902 (0%) | 0% | 65.2 | 228,235 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2026 | 1,000 | 0 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 64.75 per share. | 07 Apr 2026 | 1,000 | 153,902 (0%) | 0% | 64.8 | 64,750 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 07 Apr 2026 | 1,000 | 154,902 (0%) | 0% | 10.6 | 10,600 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 62.15 per share. | 17 Mar 2026 | 7,636 | 158,299 (0%) | 0% | 62.1 | 474,577 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 62.15 per share. | 17 Mar 2026 | 4,397 | 153,902 (0%) | 0% | 62.2 | 273,274 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2026 | 39,527 | 39,527 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2026 | 27,306 | 165,935 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2026 | 1,665 | 1,665 | - | - | Incentive Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 60.72 per share. | 09 Mar 2026 | 2,907 | 138,629 (0%) | 0% | 60.7 | 176,513 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2025 | 2,000 | 140,552 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2025 | 2,000 | 142,552 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.72 per share. | 22 Dec 2025 | 1,016 | 141,536 (0%) | 0% | 62.7 | 63,724 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 16 Dec 2025 | 2,200 | 140,752 (0%) | 0% | 10.6 | 23,320 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2025 | 2,200 | 0 | - | - | Incentive Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 61.24 per share. | 16 Dec 2025 | 2,200 | 138,552 (0%) | 0% | 61.2 | 134,728 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.02 per share. | 03 Dec 2025 | 2,058 | 138,552 (0%) | 0% | 65.0 | 133,811 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 02 Dec 2025 | 2,200 | 142,810 (0%) | 0% | 10.6 | 23,320 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2025 | 2,200 | 2,200 | - | - | Incentive Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 63.89 per share. | 02 Dec 2025 | 2,200 | 140,610 (0%) | 0% | 63.9 | 140,558 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2025 | 2,200 | 4,400 | - | - | Incentive Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 66.45 per share. | 18 Nov 2025 | 2,200 | 140,610 (0%) | 0% | 66.5 | 146,190 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 18 Nov 2025 | 2,200 | 142,810 (0%) | 0% | 10.6 | 23,320 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Nov 2025 | 2,295 | 6,600 | - | - | Incentive Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 59.55 per share. | 04 Nov 2025 | 2,295 | 140,610 (0%) | 0% | 59.5 | 136,667 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 04 Nov 2025 | 2,295 | 142,905 (0%) | 0% | 10.6 | 24,327 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 58.22 per share. | 21 Oct 2025 | 2,105 | 140,610 (0%) | 0% | 58.2 | 122,553 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 21 Oct 2025 | 2,105 | 142,715 (0%) | 0% | 10.6 | 22,313 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Oct 2025 | 2,105 | 1,000 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Oct 2025 | 2,000 | 3,105 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 60.56 per share. | 07 Oct 2025 | 2,000 | 140,610 (0%) | 0% | 60.6 | 121,120 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 07 Oct 2025 | 2,000 | 142,610 (0%) | 0% | 10.6 | 21,200 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 23 Sep 2025 | 2,000 | 142,610 (0%) | 0% | 10.6 | 21,200 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Sep 2025 | 2,000 | 5,105 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 49.28 per share. | 23 Sep 2025 | 2,000 | 140,610 (0%) | 0% | 49.3 | 98,560 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2025 | 2,000 | 7,105 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 51.29 per share. | 09 Sep 2025 | 2,000 | 140,610 (0%) | 0% | 51.3 | 102,580 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 09 Sep 2025 | 2,000 | 142,610 (0%) | 0% | 10.6 | 21,200 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 19 Aug 2025 | 2,000 | 142,610 (0%) | 0% | 10.6 | 21,200 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2025 | 2,000 | 9,105 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 38.31 per share. | 19 Aug 2025 | 2,000 | 140,610 (0%) | 0% | 38.3 | 76,620 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2025 | 2,000 | 11,105 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 36.34 per share. | 05 Aug 2025 | 2,000 | 140,610 (0%) | 0% | 36.3 | 72,680 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 05 Aug 2025 | 2,000 | 142,610 (0%) | 0% | 10.6 | 21,200 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jul 2025 | 2,000 | 13,105 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 37.47 per share. | 22 Jul 2025 | 2,000 | 140,610 (0%) | 0% | 37.5 | 74,940 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 22 Jul 2025 | 2,000 | 142,610 (0%) | 0% | 10.6 | 21,200 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2025 | 2,000 | 15,105 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 33.76 per share. | 08 Jul 2025 | 2,000 | 140,610 (0%) | 0% | 33.8 | 67,520 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 08 Jul 2025 | 2,000 | 142,610 (0%) | 0% | 10.6 | 21,200 | Common Stock |
| Rocket Pharmaceuticals Inc | Fady Ibraham Malik | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 30,000 | 30,000 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2025 | 2,000 | 17,105 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 32.91 per share. | 17 Jun 2025 | 2,000 | 140,610 (0%) | 0% | 32.9 | 65,820 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 17 Jun 2025 | 2,000 | 142,610 (0%) | 0% | 10.6 | 21,200 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 03 Jun 2025 | 2,000 | 142,610 (0%) | 0% | 10.6 | 21,200 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2025 | 2,000 | 19,105 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 31.88 per share. | 03 Jun 2025 | 2,000 | 140,610 (0%) | 0% | 31.9 | 63,760 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 20 May 2025 | 2,000 | 142,255 (0%) | 0% | 10.6 | 21,200 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 31.98 per share. | 20 May 2025 | 2,000 | 140,255 (0%) | 0% | 32.0 | 63,960 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2025 | 2,000 | 21,105 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 35.01 per share. | 06 May 2025 | 2,000 | 140,255 (0%) | 0% | 35.0 | 70,020 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 May 2025 | 2,000 | 23,105 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 06 May 2025 | 2,000 | 142,255 (0%) | 0% | 10.6 | 21,200 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Apr 2025 | 2,000 | 25,105 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 38.11 per share. | 22 Apr 2025 | 2,000 | 140,255 (0%) | 0% | 38.1 | 76,220 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 22 Apr 2025 | 2,000 | 142,255 (0%) | 0% | 10.6 | 21,200 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2025 | 2,000 | 27,105 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 36.18 per share. | 08 Apr 2025 | 2,000 | 140,255 (0%) | 0% | 36.2 | 72,360 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 08 Apr 2025 | 2,000 | 142,255 (0%) | 0% | 10.6 | 21,200 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Mar 2025 | 200 | 140,255 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Mar 2025 | 2,000 | 29,105 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 18 Mar 2025 | 2,000 | 142,455 (0%) | 0% | 10.6 | 21,200 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 43.58 per share. | 18 Mar 2025 | 2,000 | 140,455 (0%) | 0% | 43.6 | 87,160 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 44.38 per share. | 17 Mar 2025 | 4,389 | 101,005 (0%) | 0% | 44.4 | 194,784 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 58,465 | 58,465 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 39,450 | 144,844 (0%) | 0% | 0 | Common Stock |